Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 47 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

21%

10 trials in Phase 3/4

Results Transparency

12%

3 of 25 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (14)
P 1 (2)
P 2 (2)
P 4 (10)

Trial Status

Completed25
Unknown10
Recruiting4
Not Yet Recruiting3
Withdrawn2
Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT05782270Phase 4RecruitingPrimary

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

NCT05256303Not ApplicableCompleted

Rural Hospital-Level Care at Home for Acutely Ill Adults

NCT03910933Active Not Recruiting

Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative

NCT06890312Not ApplicableRecruiting

Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)

NCT07129395Active Not RecruitingPrimary

Anticoagulation Adherence Measurement Strategies

NCT06807905Phase 4Completed

Efficiency and Biocompatibility in Hemodiafiltration Procedure

NCT06779162CompletedPrimary

ROTEM-based Optimization of Anticoagulation Regimens in Lung Transplantation

NCT05305612Phase 4Enrolling By Invitation

Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions

NCT06645275Phase 4Not Yet RecruitingPrimary

Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study

NCT06476301Phase 4Not Yet RecruitingPrimary

Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves

NCT04539301RecruitingPrimary

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

NCT04071171Phase 2Completed

Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation

NCT04344717Phase 4Unknown

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

NCT06272708Recruiting

Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients

NCT06209892Not ApplicableNot Yet Recruiting

Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis

NCT05191290Phase 4Completed

Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation

NCT05555641Phase 2Unknown

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

NCT04059965Not ApplicableWithdrawnPrimary

AntiCoagulation Tracking InterVention and Evaluation

NCT01477528CompletedPrimary

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

NCT04139525Not ApplicableUnknown

Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane

Scroll to load more

Research Network

Activity Timeline